Trump officials plan coverage for weight loss drugs under Medicare and Medicaid
Such a plan was previously proposed by the Biden administration in its final months before Donald Trump re-entered the White House after winning a second term in office in the 2024 election.
Now the Trump administration intends a five-year experiment in which the Medicaid program and Medicare drug coverage plans will have the option of covering the cost of drugs selling under the names Ozempic, Wegovy, Mounjaro and Zepbound for 'weight management' purposes, the Washington Post reported on Friday morning, citing documents from the government's Centers for Medicare & Medicaid Services (CMS).
This type of medication, known as GLP-1 drugs and originally developed to treat type 2 diabetes, have gained popularity for their ability to reduce body weight by suppressing appetite and slowing digestion.
But their high cost, typically between $5,000 and $7,000 a year, has raised concerns about long-term affordability and such a plan now under consideration by Donald Trump would come at a hefty cost to the public purse.
Insurance coverage for such drugs is currently typically approved when patients have other conditions that are often tied to obesity, such as diabetes, heart disease and cancer.
The new proposed plan would permit state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs, including those from the market leaders Novo Nordisk and Eli Lilly, the report said.
Lilly and Novo are leaders in the weight-loss drug market, which some analysts expect could bring in more than $150bn in revenue by the next decade. Lilly's shares were up nearly 2% in premarket trading on Friday.
The initiative is slated to begin in April 2026 for Medicaid and January 2027 for Medicare. If it clears the way, it would mark a shift in federal policy after the administration said earlier this year that the programs would not cover weight loss drugs.
The Centers for Medicare & Medicaid Services, Lilly and Novo did not respond to Reuters' request for comment.
The plan could expose division between CMS head Mehmet Oz, who has previously praised such drugs, and health secretary Robert F Kennedy Jr, who has criticized their high cost and how they are not a substitute for a healthy lifestyle.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
8 minutes ago
- BBC News
More than 400 indirect deaths linked to LA wildfires, study suggests
More than 400 additional deaths are estimated to be linked to the wildfires that ravaged Los Angeles earlier this year, according to a new study. The figure, published on Wednesday in the medical journal JAMA, looks at deaths that have been attributed to factors caused by the wildfires, like poor air quality and delays in accessing is a higher figure than the official death count of 31 by the Los Angeles County, which tallied deaths caused directly by the study comes as hundreds of wildfires burn across the US and Canada, prompting air quality advisories in cities like Chicago, Buffalo and New York. The Palisades and Eaton fires tore through Los Angeles in January, destroying thousands of structures and leading to the evacuation of more than 100,000 Los Angeles wildfires are becoming faster and more furiousThe far-reaching impacts of wildfire smoke – and how to protect yourselfThe latest study revealed that around 440 people are estimated to have died as a result of the wildfires between 5 January and 1 February. Researchers said they tallied the figure by looking at all deaths and their causes in Los Angeles during the period of the fires, and comparing it to similar data from previous results show that there were nearly 7% more deaths during the wildfires. Some are attributed to lung and heart conditions exacerbated by smoke or stress, while others are more indirect - like delayed healthcare treatment for dialysis or cancer patients as a result of fire-related authors said that the findings underscore the need for officials to count both direct and indirect fatalities of wildfires and other climate-related emergencies when trying to quantify their impact. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies," the authors said, noting that their figures are provisional as there may have been additional fire-related deaths beyond the scope of the BBC has reached out to Los Angeles County officials for comment on the study's findings. Another study released on Wednesday in JAMA that looked at the aftermath of the 2023 Maui wildfires showed that 22% of adults in the region had reduced lung function, and half displayed symptoms of depression. The fires, which broke out in August 2023 and were the worst to affect Hawaii in recent history, killed at least 102 people and destroyed more than 2,000 structures. The authors of the Maui study said their results show the need for "sustained clinical monitoring and community-based mental health supports" months after a climate disaster.A second study on the Hawaii fires suggests that Maui saw the highest suicide and drug overdose rates in the month of the 2023 have become more frequent in recent years as a result of climate change, driven by hotter and drier weather that fuels fire addition to directly threatening lives and structures, smoke from wildfires has been shown to have adverse health effects on smoke has been found to be harmful to certain immune cells in the lungs, with a toxicity four times greater than particulates from other types of pollution. This can have a long-term impact on cardiovascular health, experts have people, pregnant women and young children, as well as those with underlying health conditions, such as heart disease or asthma, are more likely to get sick, experts say. But the smoke can also impact healthy adults.
The Guardian
15 minutes ago
- The Guardian
Tennessee demands abortion data from hospitals in ban exceptions case
The Tennessee attorney general's office has subpoenaed four medical groups in the state for records of abortions performed over the last several years as part of a lawsuit over the exceptions to the state's near-total abortion ban, court documents obtained by the Guardian show. The four subpoenas were issued this spring to Vanderbilt University medical center and a Tennessee hospital run by the national Catholic chain Ascension, as well as two smaller medical practices in Tennessee, Heritage Medical Associates and the Women's Group of Franklin. Although each subpoena is different, they broadly ask these organizations to turn over extensive information about instances in which they may have provided abortions, including the number of abortions performed since 2022 and, in some of the subpoenas, all 'documents and communications' related to those abortions. When and if the medical providers turn in the records, they are legally allowed to preserve 'all patient confidentiality as necessary', according to the subpoenas. A protective order has also been issued to block the records from being used to investigate the hospitals and medical providers outside of the scope of the lawsuit, as well as to potentially mark even the anonymized patient records as 'confidential'. The sweeping requests raise questions about red-state attempts to track abortion providers in a post-Roe v Wade US. In the three years since the US supreme court overturned Roe, reproductive rights activists have grown increasingly concerned about government efforts to collect information on abortions, especially as states such as Louisiana and Texas have recently launched efforts to penalize abortion providers. Mary Ziegler, a professor at the University of California, Davis who studies the legal history of reproduction, shared her concerns that the Tennessee subpoenas could have 'a tremendous chilling effect'. 'Republican legislators have recognized that doctors are already not performing procedures that they – Republican legislators – say are justified under exceptions,' Ziegler said. 'The message being sent here is that every single decision, even ones that would have been legal, then would be second-guessed.' The subpoenas were issued as part of a 2023 lawsuit brought by several Tennessee women and doctors who are seeking to broaden the exceptions in the state's abortion ban. Although Tennessee – like every other state with an abortion ban – technically permits abortions in medical emergencies, these women say they were denied medically necessary abortions. Doctors across the country have said that the exceptions embedded in abortion bans are worded so vaguely that they are incompatible with medical standards, forcing doctors to delay or deny care until a patient becomes sick enough to legally qualify for treatment. At least five pregnant women have reportedly died under abortion bans in Georgia and Texas. In the years since Roe fell, more pregnant Texas women have also begun to be diagnosed with sepsis – a life-threatening condition – or almost bled to death after they miscarried, according to reporting by ProPublica. Lawyers for Tennessee, however, have said in court that the state's abortion exceptions are workable as written. Some doctors' failure to accurately interpret the law does not justify amending the state's ban, Tennessee has argued, especially since the state legislature passed a bill in 2025 that sought to clarify the circumstances under which people can get abortions. The subpoenas issued to the medical providers ask them to turn over 'all protocols, policies, guidelines, practice guides or handbooks' that they have used to determine whether patients can get abortions. The subpoena for Vanderbilt also demands records from the Nashville hospital's abortion committee, which deliberates on whether and how to provide legal abortions to patients, including all 'documents and communications' that may reveal the resolution of each case considered by the committee. The other subpoenas were issued to at least one medical practice that employs a Tennessee doctor who is a part of the lawsuit. They ask those practices to count the number of abortions they have performed since 2020, two years before Roe fell. They also ask for records from instances in which doctors did not provide abortions because they felt that the Tennessee ban blocked them from doing so. The subpoenaed groups and Tennessee attorney general's office did not respond to the Guardian's requests for comment. Despite the court protections in place to keep the subpoenaed records from leaking, assurances from state officials may not be enough to quell doctors' fears of prosecution, Ziegler said. She pointed to the case of Adriana Smith, a brain-dead pregnant woman in Georgia who was kept on life support until she delivered a baby via caesarean section in June. While Georgia's attorney general said that the state's near-total abortion ban did not force doctors to keep pregnant women on life support, Smith's doctors reportedly felt that the language of the ban was so strict that they still had no choice but to keep her alive. 'Prior to any of these data requests, a lot of physicians and providers were really anxious about civil or criminal liability,' Ziegler said. 'I don't see how this is going to help matters.'
Medical News Today
34 minutes ago
- Medical News Today
Muscle loss from GLP-1 drugs like Ozempic may not be as high as thought
While past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight, other research reports that a good portion of that weight loss comes from muscle loss. A new study says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the polls estimate that one in every eight adults in the U.S. have taken a glucagon-like peptide-1 receptor agonist (GLP-1) — a class of prescription drugs originally used to treat type 2 diabetes that has gained popularity as a method of weight of GLP-1 medications include semaglutide, sold under the brand names Ozempic and Wegovy, and tirzepatide, sold under the brand names Zepbound and Mounjaro. Past studies show that adults taking a GLP-1 medication can lose between 5-15% of their starting body weight within one year. However, other research reports that about 25-39% of that weight loss is from muscle loss. Now, a new study recently published in the journal Cell Metabolism says, via a mouse model, that muscle loss from GLP-1 medications like Ozempic may not be as high as recently thought. Researchers also found that the decrease in lean muscle mass was not all from skeletal muscles, but from other body tissues, including the liver. Lean muscle mass loss not just from skeletal musclesFor this study, researchers used a mouse model to determine how GLP-1 medications like Ozempic affected lean muscle mass. Upon analysis, researchers found that Ozempic-related weight loss in mice resulted in a lean muscle mass decrease of about 10%, which is less than some previous studies report that as the mice lost weight, some skeletal muscles did decrease, while other muscles stayed the same. Researchers state that the muscle mass decrease is a return to baseline, as gaining fat is usually accompanied by a gain in skeletal muscle. Researchers found some mice experienced a decrease in strength in skeletal muscles that stayed almost the same researchers found that a good portion of the decrease in lean muscle mass did not come from skeletal muscles, but rather other tissues in the body, such as the liver, which they report reduced in size by almost half. It is not uncommon for the liver to decrease in size during weight loss, which can help reduce a person's risk for fatty liver disease.'If we want to really help the individuals who may be losing muscle mass, then we need to know that they're actually losing muscle mass,' Katsu Funai, PhD, associate professor of nutrition and integrative physiology in the University of Utah College of Health and the senior author on the study says in a press release. 'We have data in mice that suggest that things are not as straightforward as they might seem.'Working with a dietitian while taking GLP-1sMedical News Today spoke with Seth Kipnis, MD, FACS, FASMBS, director of bariatric and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, about this study, who commented that a drop in lean muscle mass is expected. Some muscle loss is inevitable'Any patient with a restricted diet and poor nutrition/protein will have a drop in muscle mass. The key of any weight loss program, surgical, medical or GLP-1 is adequate nutrition. Working with a registered dietitian is key to long-term success and avoiding complications of malnutrition.' — Seth Kipnis, MD, FACS, FASMBS'More and more people are taking these medications on a regular basis,' he continued. 'They are working well to control weight. We should know the side effects that can be caused in the long term so that patients can be counseled on how to avoid long-term issues.' Kipnis said he would like to see better long-term data as the next steps in this research. 'And are different outcomes found depending on the prescriber and the type of follow-up,' he added. 'It is our assumption that specialists in weight management and nutrition will have better outcomes than a primary care doctor that treats every disease. Obesity is a unique disease that requires specialists to manage.'Human trials needed to further analyze GLP-1s and muscle lossMNT also talked to Kais Rona, MD, a bariatric surgeon of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA.'As a physician who has treated and continues to treat many patients with GLP-1 medications such as Ozempic, I found this study quite interesting,' Rona said. 'Although the data in this study cannot be extrapolated directly to humans, it does shed some light on potentially important physiologic effects of the medication.' 'The decrease in lean mass with GLP-1 use was associated with a lesser decrease in skeletal muscle mass and a greater decrease in the size of metabolically active organs such as the liver. This can have important physiologic effects on metabolism and overall health. We also see a decrease in liver mass in patients undergoing weight loss surgery, which often leads to beneficial health effects. Importantly, this study also highlights the importance of determining the functional impact of muscle loss and whether that is reflected in a loss of strength as well.'— Kais Rona, MD'It's extremely important to continue to study the potential side effects, including the loss of lean muscle mass, associated with GLP-1 medications as it can have major effects on our healthcare system as a whole,' Rona added. 'Furthermore, we need to continue to broaden our understanding of the physiologic effects of these medications to optimize patient safety and overall outcomes.' Rona said the next best research step would be to perform randomized-controlled trials in humans to further analyze the effects of GLP-1 medications on lean mass as well as skeletal muscle mass. 'It would be important to evaluate its effects on muscle strength as well as function,' he added. 'Also to determine whether certain areas of the body are more susceptible to muscle loss as well as identifying preventive strategies to combat muscle loss.'
